Affibody CEO on recently launched psoriasis trial

David Bejker, CEO of Affibody, a Swedish biotech developing a novel psoriasis product, talks to Scrip's Lucie Ellis about the company's recently launched Phase II trial. At the recent BIO-Europe® partnering event, Bejker outlined the Phase II trial design for Affibody's psoriasis drug, ABY-035, from which first interim data are expected in the first quarter of next year. Primary endpoint data are anticipated by the end of summer 2018.